Abstract Details

Title EADC-ADNI Benchmark Images for Harmonized Hippocampal Segmentation

Topic Aging and Dementia

Presentation(s) P06 - (-)

Poster/Presentation
Number 028

Objective

Background BACKGROUND: The use hippocampal volumetry as a biomarker of Alzheimer's Disease (AD) requires standard operating procedures. A Delphi panel of experts converged on a HP for manual segmentation from magnetic resonance images (MRI).

Design/Methods DESIGN/METHODS: The consensual criteria were written in a document, open to corrections based on the feedback received during the project. Based on the HP, 5 expert tracers from independent centres segmented a sample of 40 hippocampi from 10 ADNI (Alzheimer's Disease Neuroimaging Initiative) subjects scanned at both 1.5 and 3T. Segmentations were examined slice-by-slice; volume reliability was computed through absolute and consistency 5-level intraclass correlation coefficients. Dice overlapping reliability was computed based on a formula adapted for 5 raters (intersection of the 5 segmentations / sum of the 5 absolute volumes). Tracers were asked to correct their segmentation when it diverted from the HP. Whenever the tracers' mistakes could be attributed to ambiguities in the HP written description, this was edited, resent to panelists for checking the adherence to the Delphi decisions, and to tracers for improving segmentation.

Results RESULTS: Two rounds of corrections were asked to tracers (I: major inconsistencies, II: more subtle problems due to ambiguities in the HP definitions). One round of corrections was applied to the HP. Reliability values for the corrected segmentations were: lowest absolute 5-level intra-rater, 0.943 (95% CI 0.335-0.989); lowest inter-rater: 0.943 (0.791-0.986). The mean 5-level inter-rater values were 0.96 (absolute) and 0.98 (consistency). Overlapping reliability was 0.73 for 1.5T and 0.75 for 3T images.

Conclusions CONCLUSIONS: The HP showed to produce very reliable manual segmentations. The obtained hippocampal segmentations appear as an appropriate benchmark set for certification of tracers who will carry out the validation of the HP. Boccardi et al; J Alzheimers Dis. 2011;26 Suppl3:61-75.

Authors/Disclosures
Giovanni B. Frisoni, MD (Alzheimer's Unit IRCCS) PRESENTER	No disclosure on file
Marina Boccardi, PhD (IRCCS S.Giovanni Di Dio - Fatebenefratelli)	No disclosure on file
	No disclosure on file
	No disclosure on file
Liana Apostolova, MD, FAAN (Indiana University School of Medicine)	Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NIH. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for siemens. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Apostolova has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Association. The institution of Dr. Apostolova has received research support from Roche Diagnostics. The institution of Dr. Apostolova has received research support from NIA. The institution of Dr. Apostolova has received research support from Alzheimer Association. The institution of Dr. Apostolova has received research support from AVID radiopharmaceuticals. The institution of Dr. Apostolova has received research support from Life Molecular Imaging. Dr. Apostolova has a non-compensated relationship as a advisor with FDA that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Simon Duchesne, PhD (CRULRG)	Dr. Duchesne has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Qynapse SAS. Dr. Duchesne has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Nature Group. Dr. Duchesne has received stock or an ownership interest from Qynapse SAS. Dr. Duchesne has received intellectual property interests from a discovery or technology relating to health care.
Clifford R. Jack, Jr., MD (Mayo Clinic)	The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.

��ɫ��

��ɫ��